65 related articles for article (PubMed ID: 38482415)
1. Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated
Liu Y; Ma X; Wu X; Hou X; Jin W; Fu L; Xun X; Yu Y; Shen Z
Leuk Lymphoma; 2024 May; ():1-11. PubMed ID: 38775302
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma.
Cencini E; Fabbri A; Arrigucci U; Cerase A; Bocchia M
Mediterr J Hematol Infect Dis; 2017; 9(1):e2017040. PubMed ID: 28698783
[TBL] [Abstract][Full Text] [Related]
3. De Novo CD5
Xu Y; Sun W; Li F
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e782-e790. PubMed ID: 32694049
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
[TBL] [Abstract][Full Text] [Related]
5. Toripalimab plus lenalidomide for central nervous system recurrence in refractory CD5
Chen X; Zhang Z; Zhang J; Yu Q; Qiu J; Xiao Y; Chen B; Xu P
Transl Cancer Res; 2024 Feb; 13(2):1188-1195. PubMed ID: 38482415
[TBL] [Abstract][Full Text] [Related]
6. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
[TBL] [Abstract][Full Text] [Related]
7. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
9. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.
Geng H; Jia S; Zhang Y; Li J; Yang Q; Zeng L; Zong X; Lu Y; Lu S; Zhou J; Li C; Wu D
Front Immunol; 2023; 14():1219167. PubMed ID: 37671152
[TBL] [Abstract][Full Text] [Related]
11. Bronchoalveolar Lavage as Potential Diagnostic Specimens to Genetic Testing in Advanced Nonsmall Cell Lung Cancer.
Lin X; Cai Y; Zong C; Chen B; Shao D; Cui H; Li Z; Xu P
Technol Cancer Res Treat; 2023; 22():15330338231202881. PubMed ID: 37743841
[No Abstract] [Full Text] [Related]
12. Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.
Ma D; Ma Y; Ma Y; Liu J; Gu Y; Liu N; Xiang C; Liu H; Sang W
Front Oncol; 2022; 12():941347. PubMed ID: 36081566
[TBL] [Abstract][Full Text] [Related]
13. Upcoming immunotherapeutic combinations for B-cell lymphoma.
Greve P; Meyer-Wentrup FAG; Peperzak V; Boes M
Immunother Adv; 2021 Jan; 1(1):ltab001. PubMed ID: 35919738
[TBL] [Abstract][Full Text] [Related]
14. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China.
Zhang L; Hao B; Geng Z; Geng Q
Front Immunol; 2021; 12():730666. PubMed ID: 35095833
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma.
Bastos-Oreiro M; Suárez-González J; Andrés-Zayas C; Carrión NC; Moreno S; Carbonell D; Chicano M; Muñiz P; Sanz L; Diaz-Crespo FJ; Menarguez J; Diez-Martín JL; Buño I; Martínez-Laperche C
Sci Rep; 2021 Nov; 11(1):22815. PubMed ID: 34819573
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
